03 April 2024
03 April 2024
Under the supply deal, MSD will provide the KEYTRUDA required for the trial.
Regarding the primary endpoint of treatment failure, results showed lower rates, which indicates a greater treatment benefit.
Subject to meeting specific conditions, the deal is anticipated to conclude in the last quarter of FY 2024.
The trial will evaluate the preliminary impact of the drug on plasma lipid and lipoprotein levels.
Concept’s sirolimus-coated balloons now hold five IDEs in total from the FDA.
This figure represented a slight increase from 2022 for oncology.
The trial will assess Revita’s efficacy in maintaining weight loss following the discontinuation of its GLP-1 receptor agonist (GLP-1RA) drug therapy.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
